BioMarin discontinues VOXZOGO development for Noonan syndrome in children
BioMarin announced it will discontinue development of VOXZOGO for children with Noonan syndrome.Key Highlights:Original SEC Filing: BIOMARIN PHARMACEUTICAL INC [ BMRN ] - 8-K - Sep. 15, 2026This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.